Reuters
01 Oct 2026, 12:13 UTC · 2h ago
Verdict
Headline leans bearish. We score FOGL −0.80 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Foghorn Therapeutics discontinued development of an experimental cancer drug partnered with Eli Lilly following failed early-stage trial benefits.
Newsaid on Thursday
So whatThe loss of a major partner like Lilly likely impairs future non-dilutive funding and pipeline validation.
More negative than 99% of claims this week
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Foghorn Therapeutics will cut 40% of its workforce.
Newsaid on Thursday
So whatImmediate reduction in payroll will lower the quarterly cash burn starting in Q4.
More negative than 90% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
The company discontinued the development of an experimental cancer drug following a failed early-stage trial.
More negative than 62% of ticker scores this week
A partnered drug development project was discontinued due to lack of benefit in trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
6h ago
—
No price for FOGL right now — the quote feed didn't answer.
FOGL chart →
